Risk Evaluation and Mitigation Strategies (REMS) Summary

Browse PDR's full list of drug information

FDA Date: 8/30/17

Kymriah (tisagenlecleucel) Injection REMS

Goals of the Kymriah (tisagenlecleucel) REMS Program

The goals of the Kymriah REMS Program are to mitigate the risks of cytokine release syndrome (CRS) and neurological toxicities by:
• Ensuring that hospitals and their associated clinics that dispense Kymriah are specially certified and have on-site, immediate access to tocilizumab.
• Ensuring those who prescribe, dispense, or administer Kymriah are aware of how to manage the risks of cytokine release syndrome and neurological toxicities.

REMS Elements

• Elements to Assure Safe Use

• Implementation System

Open the Full REMS Notification

REMS Summary of Terms